CAR T-Cell Therapy Nearly Eliminates Tumors in All Relapsed or Refractory Myeloma Patients in Phase 1 Trial
Updated results from an ongoing Phase 1 clinical study of bb2121, an investigational therapy for the treatment of multiple…
News
New CAR T-cell Therapy Seen to Induce Lasting Remission in Advanced Multiple Myeloma Patients
An ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) multiple myeloma patients. The new anti-BCMA…
Oncology Venture Enrolls First Multiple Myeloma Patient in Clinical Trial
Oncology Venture has enrolled the first patient into a Phase 1/2 trial of its compound APO010 in multiple myeloma. Patients in the study will…
Adding Darzalex to Standard Therapies in Multiple Myeloma Patients Continues to Show Improved Results
Adding Darzalex (daratumumab) to standard care therapies continues to show improved effectiveness in treating relapsed or refractory multiple myeloma, with no related toxicity, according to updated…
$4 Million Perelman Foundation Donation to Kick-start Myeloma Research Initiative
The first research program dedicated to the early detection and prevention of multiple myeloma will  be under way soon, thanks to a $4 million Perelman Family…
Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma
Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab), according…
Keytruda Seen to Increase Efficacy of Pomalyst and Dexamethasone in Myeloma Trial
A Phase 2 trial has shown that Keytruda (pembrolizumab) increases the effectiveness of Pomalyst (pomalidomide) and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). The study…
Bluebird to Present Follow-Up Data for CAR T-cell Therapy in Advanced Multiple Myeloma Patients
Patients with advanced multiple myeloma who received three or more lines of therapy have shown promising safety and efficacy…
Genmab-Janssen Venture to Launch 3 Clinical Trials of Multiple Myeloma Therapy Darzalex
Genmab announced that its partner Janssen Biotech will launch three novel studies to investigate the effect of Darzalex (daratumumab) in patients with multiple…
Non-profit Cancer Therapy Consultant Patient Power Praises District of Columbia Law Limiting Co-pays
The non-profit cancer-therapy consulting group Patient Power is hailing a District of Columbia law that established patient co-pay ceilings on specialty medications for diseases like multiple myeloma.
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment